All In MedTech

Reimbursement

NTAP: Medicare's new technology add-on payment for inpatient devices

NTAP explained: new technology add-on payment criteria under 42 CFR 412.87, the 65 percent cap, the Breakthrough device pathway and the application cycle.

By the All In MedTech editorial team · Published November 19, 2026 · 7 min read

NTAP, the new technology add-on payment, is an extra Medicare payment to hospitals for inpatient stays that use a qualifying new technology. It sits on top of the normal MS-DRG payment and is meant to cover part of the cost of a new device or drug while the DRG rates have not yet caught up. For most technologies Medicare pays up to 65 percent of the technology's cost, and only when the case cost exceeds the DRG payment.

The program comes from sections 1886(d)(5)(K) and (L) of the Social Security Act and is set out in 42 CFR 412.87 and 412.88. CMS runs it through the annual inpatient payment rule. This post explains the criteria, the payment formula, the alternative pathway for Breakthrough devices and the application cycle.

Why NTAP exists

In the inpatient prospective payment system (IPPS), each hospital stay is assigned to an MS-DRG and paid a set amount. That amount is based on historical claims and cost data. A new device that adds significant cost to a procedure is not reflected in those data until hospitals have used it, billed it and the data have flowed into a DRG recalibration, which takes a few years.

In the meantime, a hospital using the new device can lose money on each case, which discourages adoption. NTAP fills that gap for a limited time. For the wider picture of how DRGs and coverage fit together, see how device reimbursement works.

The three NTAP criteria

Under the traditional pathway in 412.87(b), a technology must meet all three tests.

CriterionWhat CMS asksWhere it is in the rule
NewnessIs the technology still new, meaning its cost is not yet reflected in the DRG data?412.87(b)(2)
CostWould the DRG payment be inadequate, based on a charge threshold?412.87(b)(3)
Substantial clinical improvementDoes it substantially improve diagnosis or treatment compared with what was available before?412.87(b)(1)

Newness

A technology may be considered new for 2 or 3 years after data begin to become available reflecting the inpatient code assigned to it. In practice CMS often measures this from the date the technology became commercially available in the US, usually close to its FDA authorization. Once CMS has recalibrated the DRGs on data that reflect the technology's cost, it is no longer new.

CMS also looks at whether the technology is substantially similar to one already on the market. If it uses the same or a similar mechanism of action, maps to the same DRGs and treats the same patients and condition, CMS may treat it as not new, with its newness measured from the earlier product.

Cost threshold

The cost test asks whether the charges for cases using the technology exceed a threshold amount. The regulation sets the threshold as the lesser of 75 percent of the standardized amount (adjusted to reflect the difference between cost and charges) or 75 percent of one standard deviation above the geometric mean standardized charge for the DRG. CMS publishes the dollar thresholds by DRG each year with the IPPS final rule, and they change annually, so applicants use the table for the relevant fiscal year.

Substantial clinical improvement

This is usually the hardest test. The regulation says CMS considers the "totality of the circumstances." A technology can qualify if it:

  • offers a treatment option for patients who do not respond to, or are not eligible for, current treatments;
  • lets clinicians diagnose a condition that is currently undetectable, or diagnose it earlier, with evidence that this changes patient management; or
  • significantly improves clinical outcomes, for example through fewer clinically significant adverse events or deaths, fewer later interventions, fewer hospitalizations or physician visits, faster recovery or shorter stays, better daily functioning, better quality of life, or better adherence.

The regulation allows a wide range of evidence, from clinical trials and peer-reviewed articles to case studies, consensus statements and letters from professional societies. It also notes that the condition may have low prevalence among Medicare beneficiaries, and that the improvement may apply to a subpopulation.

The payment formula

When a hospital treats a patient with an approved technology and the cost of the case exceeds the full DRG payment, 412.88 adds an amount equal to the lesser of:

  • 65 percent of the cost of the new technology, or
  • 65 percent of the amount by which the case cost exceeds the standard DRG payment.

The rate is 75 percent instead for products designated by FDA as Qualified Infectious Disease Products (QIDPs), for products approved under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD), and for one specific category of gene therapy for sickle cell disease named in the regulation.

Each approved technology has a published maximum add-on amount for the year, set in the final rule from the cost the applicant reports. Hospital case costs are estimated by applying the hospital's cost-to-charge ratio to its charges. If the case also qualifies for an outlier payment, that is calculated separately. CMS's NTAP page confirms the current percentages.

A hospital only gets NTAP when it reports the codes that identify the technology on the claim. For devices this usually means a specific ICD-10-PCS procedure code, which is why applicants often request a new code through the ICD-10 Coordination and Maintenance Committee at the same time.

The alternative pathway for Breakthrough devices

Since fiscal year 2021, CMS has offered an alternative pathway in 412.87(c) for devices in FDA's Breakthrough Devices Program. A device on this pathway does not have to show substantial clinical improvement. It must still:

  • be considered new, for 2 to 3 years from when data reflecting its inpatient code become available; and
  • meet the same cost threshold as any other applicant.

The device must have received marketing authorization as a Breakthrough device for the indication covered by its designation. A parallel pathway in 412.87(d) applies to QIDPs and LPAD products.

The current regulation, as amended in August 2026, limits the alternative pathways to applications for fiscal years 2021 through 2029. For devices, it also requires Breakthrough designation as of September 30, 2026, and marketing authorization by May 1, 2028. Anyone planning around this pathway should read the current text of 412.87(c) and the latest IPPS final rule, since the terms have changed through rulemaking.

FDA status and the May 1 deadline

Two FDA conditions apply to every NTAP application under 412.87(e) and (f).

  1. At submission, the technology must either be FDA authorized for the indication in the application, or be the subject of a complete and active FDA marketing request, with documentation that FDA has accepted or filed it.
  2. By May 1 before the fiscal year starts, the technology must have received FDA marketing authorization. A technology authorized after May 1 has to wait for the next cycle.

The federal fiscal year begins October 1, so for fiscal year 2028 the authorization deadline is May 1, 2027.

The application cycle

NTAP decisions are made once a year through the IPPS rule. The cycle runs roughly like this:

  1. Application. Submitted in the fall, about a year before the fiscal year starts, through CMS's online system, MEARIS. CMS says it only accepts NTAP applications submitted that way.
  2. Town hall meeting. CMS holds a public meeting on pending applications for substantial clinical improvement.
  3. Proposed rule. Usually published in the spring, with CMS's discussion of each application and any concerns. Public comment follows.
  4. Final rule. Usually published around August 1, with each approval or denial and the maximum add-on amount.
  5. Payment starts with discharges on October 1.

Exact dates change every year. CMS posts them on its NTAP page, and the MEARIS site holds public summaries of current applications.

How long NTAP lasts

An approved technology keeps NTAP for as long as it stays new, which in practice means two or three years. CMS reviews continuing technologies in each annual rule and ends the payment once the technology is no longer new. The list of technologies with new, continued or discontinued add-on payments is published with each IPPS final rule.

NTAP and outpatient pass-through

NTAP applies only to hospital inpatient stays. The outpatient system has its own program for new devices, the transitional pass-through payment, with different criteria and a different calendar. See device pass-through payment explained. Neither program decides coverage. For that, see Medicare NCDs vs LCDs.

What NTAP does not do

  • It does not raise the DRG payment for every case, only for cases that use the technology and whose costs exceed the DRG payment.
  • It does not guarantee Medicare coverage of the technology.
  • It does not last beyond the newness period, after which the cost is expected to show up in the DRG weights.

For official rules and the current year's details, see CMS's new medical services and new technologies page and the latest IPPS final rule in the Federal Register.

Frequently asked questions

What is NTAP?
NTAP, the new technology add-on payment, is an extra Medicare payment to hospitals on top of the MS-DRG payment for inpatient stays that use a qualifying new and costly technology.
What are the NTAP criteria?
Under 42 CFR 412.87 a technology must be new, must be too costly for the existing DRG payment under a set threshold, and must substantially improve diagnosis or treatment compared with existing options.
How much does NTAP pay?
For most technologies the add-on is the lesser of 65 percent of the technology's cost or 65 percent of the amount by which the case cost exceeds the DRG payment, with 75 percent for certain antimicrobial products.
Do Breakthrough devices automatically get NTAP?
No. Under the alternative pathway they do not have to show substantial clinical improvement, but they must still meet the newness and cost criteria and apply through the annual process.

For information only, not medical, legal or investment advice. Facts about FDA, CMS and SEC rules are current as of the publication date; check the linked official source for changes.

Keep reading